These findings offer valuable insights into the potential role of GLP-1 analogs in managing RA patients with co-existing diabetes and provide perspective on inflammatory pathways that may be particularly relevant in persons with RA and T2DM. This evidence concerns the gene GCG and rheumatoid arthritis.